RGEN as reported
Repligen Corporation reported $785M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.
$785M
Revenue, trailing twelve months · to Q2 2026 · +16% against the twelve months before
- Net Income
- $42M
Net Income · −400% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $112M
Free Cash Flow · +2.8% year on year · trailing twelve months to Q2 2026
- Op Margin
- 8.2%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $785M | +16% | Q2 2026 |
| Net Income | $42M | −400% | Q2 2026 |
| EPS | $0.73 | −381% | Q2 2026 |
| Gross Margin | 54% | n/a | Q2 2026 |
| Op Margin | 8.2% | n/a | Q2 2026 |
| Net Margin | 5.3% | n/a | Q2 2026 |
| ROE | 1.7% | n/a | Q2 2026 |
| ROA | 1.2% | n/a | Q2 2026 |
| ROIC | 2.0% | n/a | Q2 2026 |
| Free Cash Flow | $112M | +2.8% | Q2 2026 |
| P/E | 247 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Repligen Corporation (RGEN) - Revenue & ProfitRevenue & ProfitRepligen Corporation (RGEN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #11 of 27 by Smart Score